Study of Fish Oil to Reduce ALT Levels in Adolescents
Randomized Trial of Fish Oil Versus Placebo to Reduce ALT Levels in Overweight Adolescents
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Boston University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI (kg/m2) at or above the 95th percentile for age and gender
- Weight below 400 pounds (less than 182 kilograms)
- Persistent elevation of ALT (41-90 UI/L at study screening)
- Presence of hepatic steatosis on abdominal CT-scan
- Able to give informed consent/assent
Exclusion Criteria:
- Type 2 diabetes mellitus
- Prior drug treatment for diabetes, insulin insensitivity, or weight loss medications six months before screening
- Use of prescription strength glucocorticoids within three months before screening
- History of syndrome or medical disorder associated with significant obesity
- Participation in a weight loss program within six months of screening resulting in 5% or more weight loss
- History of weight loss surgery
- Alcohol use more than twice weekly or more than 3 alcohol containing beverages within a 24-hour period in the past six months
- Known or suspected bleeding condition
- History of liver disease including prior liver biopsy with NASH type 2 or cirrhosis
- Former or present positive blood tests for Infectious hepatitis B or C, autoimmune hepatitis, Wilson disease, Alpha-1 anti-trypsin deficiency, Iron storage disease, or high TSH
- History of past or current pregnancy
- Use of illegal/illicit drugs
- Other conditions contraindicated or cause for caution in the use of fish oil
- Unable to comply with the protocol
- Any other serious disease determined by the study gastroenterologists and physician nutrition specialist as potential study risk for the patient
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Participants will receive 2 capsules of 1 gram of placebo with meals twice a day for a period of six months (including a ramp up period of three weeks)
Other Names:
|
|
Experimental: Fish oil
Omega-3-acid ethyl esters in the form of fish oil capsules with ram up from 1g to 4 g/day (capsules 1g)
|
Participants will receive 2 capsules of 1 gram of fish oil with meals twice a day for a period of six months (including a ramp up period of three weeks)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Efficacy parameters: Characterize the reduction in ALT levels.
Time Frame: 3 and 6 months from baseline
|
3 and 6 months from baseline
|
|
Safety/compliance parameters: Describe the safety blood tests results, review of systems, and physical examination at baseline, mid point, and end of treatment, as well as identify adverse events and compliance parameters at study contacts.
Time Frame: From baseline to end of treatment
|
From baseline to end of treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Improvement in waist circumference, insulin and lipid indices, and other metabolic parameters.
Time Frame: 3 and 6 months from baseline
|
3 and 6 months from baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Carine M Lenders, MD, MS, ScD, Boston University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IIT40
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.